The development of supportive-care agents for patients with cancer.
As the population ages, a dramatic increase in the number of cases of cancer is expected and the need for supportive-care agents, those used to ameliorate some of the side effects of cancer or its treatment, becomes more urgent. At present, supportive-care products are available and new agents are being developed with novel mechanisms of action or modifications of existing agents that improve performance. Because of the urgent need for such products, efficient development is required to deliver useful products to patients as rapidly as possible. This chapter uses actual examples to illustrate the stages of drug development, phase I through phase 3.
Neumann
Theresa K
TK
Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1699, USA.
Foote
MaryAnn
M
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000068256:Darbepoetin alfa; D017277:Drug Approval / Q000331:legislation & jurisprudence; D015195:Drug Design; D004341:Drug Evaluation / Q000379:methods; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D051523:Fibroblast Growth Factor 7; D005346:Fibroblast Growth Factors / Q000627:therapeutic use*; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D009503:Neutropenia / Q000188:drug therapy*; D010166:Palliative Care / Q000379:methods* / Q000639:trends; D011092:Polyethylene Glycols; D011788:Quality of Life; D011994:Recombinant Proteins; D013280:Stomatitis / Q000188:drug therapy* / Q000209:etiology; D014481:United States
D000970:Antineoplastic Agents; C496453:FGF7 protein, human; D011994:Recombinant Proteins; D004921:Erythropoietin; D051523:Fibroblast Growth Factor 7; D016179:Granulocyte Colony-Stimulating Factor; D000068256:Darbepoetin alfa; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D005346:Fibroblast Growth Factors; D000069585:Filgrastim